Unstable angina / non ST elevation myocardial infarction chronic kidney disease: Difference between revisions
Smitakohli (talk | contribs) No edit summary |
Varun Kumar (talk | contribs) No edit summary |
||
| Line 14: | Line 14: | ||
==ACC / AHA Guidelines (DO NOT EDIT) <ref name=" | ==ACC / AHA Guidelines (DO NOT EDIT) <ref name="pmid21444889">{{cite journal |author=Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE, Ettinger SM, Fesmire FM, Ganiats TG, Jneid H, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP |title=2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines |journal=[[Circulation]] |volume= |issue= |pages= |year=2011 |month=March |pmid=21444889 |doi=10.1161/CIR.0b013e31820f2f3e |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=21444889 |accessdate=2011-03-31}}</ref>== | ||
{{cquote| | {{cquote| | ||
===Class I=== | ===Class I=== | ||
1. [[Creatinine clearance]] should be estimated in [[UA]] / [[NSTEMI]] patients and the doses of renally cleared | '''1.''' [[Creatinine clearance]] should be estimated in [[UA]] / [[NSTEMI]] patients and the doses of renally cleared medications should be adjusted | ||
according to the pharmacokinetic data for specific medications. ''(Level of Evidence: B)'' | |||
2. | '''2.''' Patients undergoing [[cardiac catheterization]] with receipt of contrast media should receive adequate preparatory hydration. ''(Level of Evidence: B)'' | ||
contrast | |||
'''3.''' Calculation of the contrast volume to [[creatinine clearance]] ratio is useful to predict the maximum volume of contrast media that can be given without significantly increasing the risk of [[contrast-associated nephropathy]]. ''(Level of Evidence: B)'' | |||
===Class II=== | |||
1. An invasive strategy is reasonable in patients with mild (stage II) and moderate (stage III) [[chronic kidney disease]]. ''(Level of Evidence: B)'' (There are insufficient data on benefit/risk of invasive strategy in [[UA]] / [[NSTEMI]] patients with advanced [[chronic kidney disease]] [stages IV, V].)}} | |||
==See Also== | ==See Also== | ||
| Line 30: | Line 36: | ||
*The 2009 ACC/AHA Focused update on the guidelines for STEMI and PCI<ref name="2009 STEMI guidelines">[http://content.onlinejacc.org/cgi/content/full/j.jacc.2009.10.015]</ref> | *The 2009 ACC/AHA Focused update on the guidelines for STEMI and PCI<ref name="2009 STEMI guidelines">[http://content.onlinejacc.org/cgi/content/full/j.jacc.2009.10.015]</ref> | ||
*2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction<ref name="pmid21444889">{{cite journal |author=Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE, Ettinger SM, Fesmire FM, Ganiats TG, Jneid H, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP |title=2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines |journal=[[Circulation]] |volume= |issue= |pages= |year=2011 |month=March |pmid=21444889 |doi=10.1161/CIR.0b013e31820f2f3e |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=21444889 |accessdate=2011-03-31}}</ref> | |||
==References== | ==References== | ||
Revision as of 05:45, 3 April 2011
| Cardiology Network |
 Discuss Unstable angina / non ST elevation myocardial infarction chronic kidney disease further in the WikiDoc Cardiology Network |
| Adult Congenital |
|---|
| Biomarkers |
| Cardiac Rehabilitation |
| Congestive Heart Failure |
| CT Angiography |
| Echocardiography |
| Electrophysiology |
| Cardiology General |
| Genetics |
| Health Economics |
| Hypertension |
| Interventional Cardiology |
| MRI |
| Nuclear Cardiology |
| Peripheral Arterial Disease |
| Prevention |
| Public Policy |
| Pulmonary Embolism |
| Stable Angina |
| Valvular Heart Disease |
| Vascular Medicine |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [3] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview of Chronic Kidney Disease in UA / NSTEMI
Chronic kidney disease(CKD) constitutes a risk factor for adverse outcomes after MI. It is a coronary artery disease equivalent as well as a risk factor for progression of CAD. There is limited evidence available on the management of UA/NSTEMI in this group due to their underrepresentaion in randomized trials. But limited evidence shows that cardiovascular medications and interventional strategies can be applied safely in those with renal impairment and provide therapeutic benefits. However, use of some of the medications and some strategies can be limited in the setting of ACS in these patients, bleeding complications are higher in this patient subgroup because of platelet dysfunction and dosing errors; benefits of fibrinolytic therapy, antiplatelet agents, and anticoagulants can be outweighed by bleeding complications; and use of renin angiotensin-aldosterone inhibitors can impose a greater risk because of the complications of hyperkalemia and worsening renal function in the CKD patient. Angiography carries an increased risk of contrast-induced nephropathy. A diagnosis of renal dysfunction is critical to proper medical therapy of UA/NSTEMI. Many cardiovascular drugs used in UA/NSTEMI patients are renally cleared; their doses should be adjusted for estimated creatinine clearance. Use of the Cockroft-Gault formula to generate dose adjustments is recommended.
In association with National Kidney Foundation, AHA advisory recommends that all patients with CAD be screened for evidence of kidney disease by estimating glomerular filtration rate, testing for microalbuminuria, and measuring the albumin-to creatinine ratio(Class IIa, Level of Evidence: C).
ACC / AHA Guidelines (DO NOT EDIT) [1]
| “ |
Class I1. Creatinine clearance should be estimated in UA / NSTEMI patients and the doses of renally cleared medications should be adjusted according to the pharmacokinetic data for specific medications. (Level of Evidence: B) 2. Patients undergoing cardiac catheterization with receipt of contrast media should receive adequate preparatory hydration. (Level of Evidence: B) 3. Calculation of the contrast volume to creatinine clearance ratio is useful to predict the maximum volume of contrast media that can be given without significantly increasing the risk of contrast-associated nephropathy. (Level of Evidence: B) Class II1. An invasive strategy is reasonable in patients with mild (stage II) and moderate (stage III) chronic kidney disease. (Level of Evidence: B) (There are insufficient data on benefit/risk of invasive strategy in UA / NSTEMI patients with advanced chronic kidney disease [stages IV, V].) |
” |
See Also
Sources
- The ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction [2]
- The 2009 ACC/AHA Focused update on the guidelines for STEMI and PCI[3]
- 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction[1]
References
- ↑ 1.0 1.1 Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE, Ettinger SM, Fesmire FM, Ganiats TG, Jneid H, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP (2011). "2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/CIR.0b013e31820f2f3e. PMID 21444889. Retrieved 2011-03-31. Unknown parameter
|month=ignored (help) - ↑ Anderson JL, Adams CD, Antman EM; et al. (2007). "ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine". JACC. 50 (7): e1–e157. PMID 17692738. Text "doi:10.1016/j.jacc.2007.02.013 " ignored (help); Unknown parameter
|month=ignored (help) - ↑ [1]